In a recent case series presented at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, dupilumab (Dupixent) treatment has been shown to be safe and generally well-tolerated in patients with chronic obstructive pulmonary disease (COPD) and elevated eosinophil counts.1
The data, suggesting that dupilumab’s utilization was linked to fewer exacerbations and improvement in patients COPD symptom, as suggested by patient-reported outcomes. This analysis, presented in a poster session at ATS, was titled ‘Real-World Experience of Dupilumab Treatment for Patients With COPD’ and authored by such investigators as Ophir Freund, MD, of Tel Aviv Sourasky Medical Center.1
Prior to this research, dupilumab was noted as having recently demonstrated efficacy in individuals with COPD characterized by…